Clinical Trials Sponsored by Janssen Research & Development, LLC

Total 1109 results

Janssen Research & Development, LLC
Eisai Inc.

Completed

A Study of Single and Multiple Doses of Rabeprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Months Old, Inclusive

Gastroesophageal Reflux Disease (GERD)

United States, Poland, United Kingdom, Belgium, Brazil
Janssen Research & Development, LLC
Mayo Clinic

Recruiting

A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)

Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

United States, Australia, Israel
ViiV Healthcare
Janssen Research & Development, LLC

Recruiting

Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics

HIV Infections

United States
Grünenthal GmbH
Janssen Research & Development, LLC

Completed

Pharmacokinetic, Efficacy and Safety Study of Tapentadol Oral Solution in Children With Postoperative Pain

Postoperative Pain | Acute Pain

United States
Duke University
Janssen Research & Development, LLC

Completed

CTC Immune Checkpoint

Prostate Cancer

United States
Janssen Research & Development, LLC
Schering-Plough

Terminated

A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)

Juvenile Idiopathic Arthritis

Poland, United States, Germany, Belgium, Canada, Finland, Netherlands, Russian Federation, Brazil, Austria, Lithuania, Mexico
Janssen Research & Development, LLC
Innovaderm Research Inc.

Completed

Analysis of Non-Invasively Collected Microneedle Device Samples From Mild Plaque Psoriasis for Use in Transcriptomics Profiling

Psoriasis Vulgaris

Canada
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC

Completed

An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis

Colitis, Ulcerative

United States, Canada, France, Poland, Ukraine, Germany, Israel, Bulgaria, India, Romania, Serbia, South Africa, Japan, Australia, Netherlands, Sweden, Belgium, New Zealand, Russian Federation, Czech Republic, Hungary, Austria, Denmark and more
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC

Completed

An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis

Colitis, Ulcerative

United States, France, Poland, Ukraine, Germany, Belgium, Israel, Bulgaria, India, Romania, Serbia, South Africa, Japan, Canada, Australia, Netherlands, New Zealand, Russian Federation, Czech Republic, Hungary, Austria, Denmark, Lit... and more
Alliance Foundation Trials, LLC.
Janssen Research & Development, LLC

Active, not recruiting

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

Prostate Cancer

United States
Merck Sharp & Dohme LLC
Janssen Research & Development, LLC

Completed

Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC
Janssen Research & Development, LLC

Completed

Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)

Chronic Hepatitis C Virus
Pharmacyclics LLC.
Janssen Research & Development, LLC; Celgene Corporation

Completed

Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

United States, United Kingdom, Belgium, Germany
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC

Terminated

An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis

Colitis, Ulcerative

United States, Poland, Germany, France, India, Romania, Serbia, Ukraine, Israel, Canada, Netherlands, Sweden, New Zealand, Russian Federation, Australia, Belgium, Hungary, Bulgaria, Slovakia, Latvia, Lithuania, Austria
Janssen Research & Development, LLC
The Scripps Research Institute

Withdrawn

Effect of JNJ 31001074 on Urge to Drink in Alcohol-Dependent Adults

Alcoholism

United States
AC Immune SA
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease

Brain Diseases | Central Nervous System Diseases | Cognitive Impairment | Dementia | Tauopathies | Mild Cognitive Impairment | Alzheimer's Disease

United Kingdom, Finland, Netherlands, Sweden
University of Washington
Janssen Research & Development, LLC

Terminated

Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Double-Negative Prostate Carcinoma

United States
OncoVerity, Inc.
Janssen Research & Development, LLC; argenx

Completed

A Study of ARGX-110 in Participants With Advanced Malignancies

Neoplasms

France, Belgium
Janssen Research & Development, LLC
Bristol-Myers Squibb

Completed

A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies

Hematologic Neoplasms

United States, Poland, Spain, Israel, Turkey, Australia
European Myeloma Network
Janssen Research & Development, LLC

Active, not recruiting

Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma (Perseus)

Multiple Myeloma

Norway, Denmark, Netherlands, Czechia, Australia, Turkey, Spain, Belgium, Switzerland, France, Greece, Italy, Poland
Janssen Research & Development, LLC
Bristol-Myers Squibb

Completed

A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery (AXIOMATIC-TKR)

Arthroplasty, Replacement, Knee

Israel, Belgium, Italy, United States, Spain, Hungary, Portugal, Russian Federation, Japan, Turkey, Ukraine, Greece, Poland, Argentina, Brazil, Bulgaria, Canada, South Africa
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Terminated

Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab

Alzheimer Disease

United States
University of Oxford
Janssen Research & Development, LLC

Completed

Effects of Bupropion in Depression

Depression

United Kingdom
Janssen Research & Development, LLC
Hoffmann-La Roche

Terminated

Safety and Efficacy of EVT 101 in Treatment-Resistant Depression

Depression

United States
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Completed

Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer Disease

United States
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Completed

Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Japan
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Completed

Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease

Alzheimer Disease

Japan
JANSSEN Alzheimer Immunotherapy Research & Development...
Pfizer

Terminated

Retrieval of Patient Information After Discontinuation (RAPID)

Alzheimer's Disease
JANSSEN Alzheimer Immunotherapy Research & Development...
Pfizer

Completed

Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease (ACCTION)

Alzheimer's Disease

United States
JANSSEN Alzheimer Immunotherapy Research & Development...
Pfizer

Completed

Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease (SUMMIT AD)

Alzheimer's Disease

United States
Janssen Research & Development, LLC
Cegedim Strategic Data

Completed

PRILIGY Usage Patterns in Selected Populations

Sexual Dysfunction, Physiological
JANSSEN Alzheimer Immunotherapy Research & Development...
Pfizer

Terminated

A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States, Canada, Austria
JANSSEN Alzheimer Immunotherapy Research & Development...
Pfizer

Completed

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)

Alzheimer's Disease

United States, Germany, Canada, Austria
JANSSEN Alzheimer Immunotherapy Research & Development...
Pfizer

Completed

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)

Alzheimer's Disease

United States
Janssen Research & Development, LLC
Bristol-Myers Squibb

Recruiting

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation (LIBREXIA-AF)

Atrial Fibrillation

Belgium, United States, Italy, Japan, Taiwan, South Africa, Korea, Republic of, Poland, Chile, Serbia, Israel, France, Netherlands, Denmark, Hungary, Argentina, Australia, China, Spain, New Zealand, Czechia, Bulgaria, Croatia, Malaysia, German... and more
Janssen Research & Development, LLC
Bristol-Myers Squibb

Recruiting

A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms

Myeloproliferative Neoplasms

United States, United Kingdom
University of Oxford
Janssen Research & Development, LLC

Recruiting

Oxford Pre-cancerous Lymphoproliferative Disorders Study (OxPLoreD)

Pre-cancerous Lymphoproliferative Disorders

United Kingdom
The Rogosin Institute
Janssen Research & Development, LLC

Completed

Inflammatory and Immune Profiling of Kidney Tissue Obtained From Patients With Newly Diagnosed Kidney Disease

Proteinuria | Chronic Kidney Disease | Kidney Injury

United States
OncoVerity, Inc.
Janssen Research & Development, LLC; argenx

Active, not recruiting

A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy (CULMINATE)

Leukemia, Myeloid, Acute

Switzerland, Israel, Spain, France, Turkey, Italy, Australia, Brazil, Russian Federation
OncoVerity, Inc.
Janssen Research & Development, LLC; argenx

Active, not recruiting

Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia (ELEVATE)

Leukemia, Myeloid, Acute

Canada, United States, Poland, Switzerland, Germany
Janssen Research & Development, LLC
Bristol-Myers Squibb

Completed

A Study of JNJ-70033093 and Digoxin in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC
Bristol-Myers Squibb

Completed

A Study of JNJ-70033093 in Healthy Participants

Healthy

Belgium
AbbVie
Janssen Research & Development, LLC; Forest Laboratories

Completed

Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Receiving Porcine-derived Pancreatic Enzyme Replacement Therapy

Cystic Fibrosis

United States
Pharmacyclics Switzerland GmbH
Janssen Research & Development, LLC

Completed

Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

Spain, Germany, Turkey, Greece, Italy, Czechia
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Completed

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

Alzheimer's Disease

United States, Korea, Republic of
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Terminated

A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease

Alzheimer Disease

United States
JANSSEN Alzheimer Immunotherapy Research & Development...
Pfizer

Completed

AAB-001 in Patients With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Janssen Research & Development, LLC
Bristol-Myers Squibb

Recruiting

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)

Acute Coronary Syndrome

Taiwan, Korea, Republic of, United States, Italy, South Africa, Belgium, Argentina, Israel, Malaysia, Romania, Serbia, China, Australia, Netherlands, United Kingdom, Denmark, Czechia, Hungary, Japan, France, Canada, Bulgaria, Spain, T... and more
OncoVerity, Inc.
Janssen Research & Development, LLC; argenx

Completed

A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Switzerland, France
European Myeloma Network
Janssen Research & Development, LLC

Active, not recruiting

Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone (EMN14)

Multiple Myeloma

Netherlands, Belgium, Germany, Spain, Czechia, Greece, Italy, Denmark, Serbia, Turkey

Clinical Trials Sponsored by Janssen Research & Development, LLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations